Results

• All
• Video
• Audio
• Images

• Most recent
• Filter by category

1–3 of 3 results for KSI-301

• 

  Tarcocimab Tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for DME: First-Time Efficacy, Durability and Safety Results of the GLEAM and GLIMMER Phase 3 studies

  Charles C Wykoff, MD, PhD, FASRS

  Annual Meeting Talks

  2023

• 

  One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO

  Mark R. Barakat, MD

  Updates from the Field

  2020

• 

  First Results From a Phase 1B Multiple-Dose Study of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate (ABC) With Extended Durability

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2019